Symbol | Exchange | Currency |
|---|
Leerink Partners analyst Puneet Souda maintained a Buy rating on NeoGenomics (NASDAQ:NEO) on Tuesday, setting a price target of $63, which is approximately 22.21% above the present...
NeoGenomics (NEO) provides cancer genetics testing services. It helps doctors diagnose and treat cancer and supports pharmaceutical companies in drug development and clinical...
NeoGenomics Inc (NASDAQ: NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue of $101 million increased 37% Y/Y...
NEO Price Analysis – August 17 NEO/USD is trading downwards, just like any other altcoins in the crypto market as the crypto touches the daily high of $58.60. NEO/USD Market Key...
NEO Price Analysis – July 18 After touching the daily high of $31, the bears are taking full control of the market lowering the price to the $28 level. NEO/USD Market Key Levels:...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Sell | Sell | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 147.09 | 148.82 | 146.56 | -1.70 | -1.14% | 37.37M | NASDAQ | |||
| 368.72 | 371.28 | 367.16 | -4.34 | -1.16% | 5.17M | NASDAQ | |||
| 2,849.40 | 2,864.40 | 2,843.40 | -22.8 | -0.79% | 495.57K | NASDAQ | |||
| 44.60 | 46.37 | 44.56 | -1.44 | -3.13% | 19.61M | NYSE | |||
| 3.24 | 3.29 | 3.24 | -0.100 | -2.99% | 25.15K | NYSE | |||
| 88.81 | 89.18 | 88.81 | +0.69 | +0.78% | 41.80K | NASDAQ | |||
| 44.05 | 44.46 | 43.95 | -0.42 | -0.94% | 8.70M | NYSE | |||
| 2.88 | 2.90 | 2.78 | +0.110 | +3.97% | 499.37K | NYSE | |||
| 1.94 | 1.98 | 1.93 | -0.010 | -0.51% | 691.93K | NYSE | |||
| 57.50 | 57.53 | 57.50 | -0.60 | -1.03% | 18.09K | NASDAQ | |||
| 43.39 | 44.97 | 43.25 | -1.24 | -2.78% | 133.46K | NASDAQ | |||
| 28.73 | 29.19 | 28.22 | +0.10 | +0.35% | 30.14M | NYSE | |||
| 1.23 | 1.23 | 1.22 | -0.0100 | -0.81% | 26.74K | NASDAQ | |||
| 430.40 | 441.52 | 428.11 | -10.25 | -2.33% | 3.67M | NASDAQ | |||
| 67.00 | 68.90 | 67.00 | -2.68 | -3.85% | 24.97K | NASDAQ |
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.